Last Updated: June 25, 2026

Litigation Details for Telcordia Tech Inc. v. CISCO Systems Inc. (D. Del. 2004)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Telcordia Tech Inc. v. CISCO Systems Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: Telcordia Tech Inc. v. CISCO Systems Inc. (D. Del. 2004)

Last updated: May 11, 2026

What does the litigation between Telcordia Tech Inc. and Cisco Systems Inc. (1:04-cv-00876) cover, and what is the patent-case outcome?

What is the case and where is it docketed?

Telcordia Technologies Inc. v. Cisco Systems Inc.

  • Case number: 1:04-cv-00876
  • Caption (as provided): Litigation summary and analysis for Telcordia Tech Inc. v. CISCO Systems Inc.
  • Jurisdiction: Federal district court docket (exact district and judge not provided in the prompt)

What patents and claims are at issue?

No patent numbers, asserted claims, claim construction positions, or infringement theories are provided in the prompt. Without the specific asserted patent set and the case’s litigated claim set, a complete litigation summary and infringement/validity analysis cannot be produced.

What procedural posture exists?

No procedural milestones are provided (e.g., scheduling order dates, Markman hearing date, summary judgment rulings, jury verdict dates, claim construction order, stipulations, or appellate activity). Without those events and dates, a litigation chronology is not supportable.

What is the outcome (trial, settlement, or dismissal)?

No disposition is provided (verdict, judgment, settlement amount, consent decree, dismissal basis, or appeal outcome). Without a verified outcome, any “analysis” would be speculative.

What does Telcordia typically litigate in this technology area (high-level context)?

The prompt provides no technology domain (VoIP, networking protocols, signaling, optical transport, OSS/BSS, billing, E911, etc.). Without knowing the technological field, mapping the case to the relevant Telcordia patent families is not possible.

What is needed for a Bloomberg-style patent litigation analysis?

A proper, decision-grade analysis requires, at minimum, the following docket-grounded facts:

  • Asserted patents and their publication/grant details
  • Claim chart scope (independent and asserted dependent claims)
  • Markman constructions and which terms were dispositive
  • Invalidity theories (prior art references, anticipation/obviousness framework, motivation-to-combine findings)
  • Infringement theories (how accused Cisco products/practices map to claim limitations)
  • Final disposition (judgment vs settlement) and the basis (non-infringement, invalidity, estoppel, or procedural dismissal)

None of these elements are included in the provided material. Under the operating constraints, an incomplete or unverifiable summary must not be generated.


Key Takeaways

  • The provided prompt includes only the case caption and number (1:04-cv-00876); it does not include asserted patents, claim scope, procedural rulings, or disposition.
  • A complete patent litigation summary and outcome analysis cannot be produced from the supplied information.

FAQs

  1. What is 1:04-cv-00876?
    A federal district court docket entry for Telcordia Technologies Inc. v. Cisco Systems Inc., as identified by the case number provided.

  2. Which patents did Telcordia assert?
    Not provided in the prompt.

  3. Did the court hold any claims invalid or find infringement?
    Not provided in the prompt.

  4. Was the case resolved by trial or settlement?
    Not provided in the prompt.

  5. What products did Cisco face allegations over?
    Not provided in the prompt.


References

[1] No sources were provided in the prompt to cite.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.